Kari Alitalo Selected Research

Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)

6/2015	Growth factor therapy and lymph node graft for lymphedema.
2/2014	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.
3/2013	Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
2/2010	Structural determinants of growth factor binding and specificity by VEGF receptor 2.
4/2009	VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
6/2008	The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
4/2007	VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.
9/2006	Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
10/2003	Vascular endothelial growth factor-D expression in human atherosclerotic lesions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kari Alitalo Research Topics

Disease

79	Neoplasms (Cancer) 01/2022 - 04/2002
30	Inflammation (Inflammations) 01/2021 - 05/2002
27	Neoplasm Metastasis (Metastasis) 01/2020 - 04/2002
16	Lymphedema (Milroy Disease) 01/2022 - 07/2002
14	Lymphatic Metastasis 01/2020 - 04/2002
10	Hyperplasia 01/2020 - 03/2004
10	Edema (Dropsy) 01/2020 - 09/2002
9	Carcinogenesis 01/2016 - 12/2004
8	Hypoxia (Hypoxemia) 01/2020 - 10/2004
7	Hypertrophy 01/2019 - 10/2008
7	Ischemia 11/2016 - 06/2003
7	Carcinoma (Carcinomatosis) 03/2013 - 02/2004
6	Adenoma (Adenomas) 01/2021 - 05/2008
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 02/2005
6	Melanoma (Melanoma, Malignant) 01/2017 - 08/2005
6	Cardiomegaly (Heart Hypertrophy) 11/2016 - 10/2008
6	Pathologic Neovascularization 01/2015 - 09/2008
5	Breast Neoplasms (Breast Cancer) 09/2020 - 04/2002
5	Atherosclerosis 09/2017 - 10/2003
5	Arteriosclerosis 03/2010 - 05/2002
4	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 05/2014
4	Vascular Remodeling 01/2017 - 09/2002
4	Obesity 11/2016 - 02/2015
4	Wounds and Injuries (Trauma) 07/2008 - 07/2002
3	Insulin Resistance 12/2021 - 02/2015
3	Heart Failure 11/2016 - 12/2012
3	Pathologic Processes 11/2015 - 08/2004
3	Hypertension (High Blood Pressure) 07/2013 - 10/2008
3	Ovarian Neoplasms (Ovarian Cancer) 03/2013 - 02/2008
3	Infections 02/2011 - 02/2005
3	Hemorrhage 01/2011 - 09/2006
2	Lung Injury 01/2022 - 08/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 11/2002
2	Infarction (Infarctions) 01/2020 - 09/2008
2	Glioma (Gliomas) 12/2017 - 07/2003
2	Chylothorax 09/2017 - 02/2014
2	Weight Gain 11/2016 - 02/2015
2	Adenocarcinoma 01/2016 - 10/2010
2	Glaucoma 09/2014 - 09/2014
2	Hemangioma (Angioma) 01/2013 - 01/2013
2	Rheumatoid Arthritis 05/2011 - 01/2002

Drug/Important Bio-Agent (IBA)

65	Vascular Endothelial Growth Factor CIBA 01/2022 - 01/2002
56	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 03/2002
38	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/2022 - 03/2002
25	Vascular Endothelial Growth Factor DIBA 01/2016 - 01/2002
18	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 05/2002
17	LigandsIBA 11/2021 - 04/2002
15	Vascular Endothelial Growth Factor BIBA 01/2021 - 02/2005
13	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 06/2002
10	CytokinesIBA 01/2021 - 03/2002
9	Angiopoietin-2IBA 01/2021 - 09/2002
9	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 06/2015 - 10/2003
8	AngiopoietinsIBA 01/2022 - 05/2010
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2004
8	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2020 - 04/2002
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2015 - 09/2002
8	Phosphotransferases (Kinase)IBA 10/2015 - 09/2003
7	Transcription Factors (Transcription Factor)IBA 10/2018 - 03/2005
6	AntibodiesIBA 01/2022 - 04/2002
6	Messenger RNA (mRNA)IBA 01/2020 - 01/2002
5	Blocking AntibodiesIBA 01/2021 - 09/2010
5	EnzymesIBA 09/2020 - 04/2002
5	Vascular Endothelial Growth FactorsIBA 01/2020 - 09/2002
5	CollagenIBA 05/2015 - 06/2003
5	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 05/2011 - 03/2002
4	TIE Receptors (TIE Receptor Tyrosine Kinases)IBA 01/2022 - 05/2010
4	CateninsIBA 01/2022 - 05/2014
4	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2020 - 09/2002
4	Therapeutic UsesIBA 10/2015 - 01/2005
4	Angiopoietin-1IBA 06/2009 - 03/2003
4	Collagen Type XVIII (Type XVIII Collagen)IBA 12/2007 - 10/2002
4	EndostatinsIBA 12/2007 - 10/2002
3	Insulin (Novolin)FDA Link 12/2021 - 10/2006
3	IntegrinsIBA 01/2020 - 01/2012
3	Keratin-14 (Keratin 14)IBA 11/2016 - 05/2009
3	LipidsIBA 04/2016 - 03/2010
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2015 - 03/2002
3	Biological ProductsIBA 04/2011 - 08/2004
2	AntigensIBA 01/2020 - 05/2009
2	Bevacizumab (Avastin)FDA Link 07/2019 - 11/2012
2	Doxycycline (Periostat)FDA LinkGeneric 09/2017 - 02/2014
2	Anti-Bacterial Agents (Antibiotics)IBA 11/2016 - 02/2005
2	CarcinogensIBA 01/2016 - 12/2007
2	Tyrosine Kinase InhibitorsIBA 10/2015 - 06/2008
2	Angiotensin IIIBA 10/2015 - 10/2008
2	Annexin A1IBA 09/2015 - 09/2014
2	Indicators and Reagents (Reagents)IBA 05/2015 - 08/2005
2	Membrane Proteins (Integral Membrane Proteins)IBA 05/2015 - 03/2005
2	LDL Receptors (LDL Receptor)IBA 06/2014 - 08/2005
2	Lipoproteins (Lipoprotein)IBA 06/2014 - 08/2005
2	Apolipoprotein B-48IBA 06/2014 - 08/2005
2	Placenta Growth FactorIBA 08/2013 - 10/2010
2	SaltsIBA 07/2013 - 05/2009
2	Pharmaceutical PreparationsIBA 08/2012 - 05/2010
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2012 - 10/2010
2	tyrosine receptor (receptor, tyrosine)IBA 01/2012 - 09/2003

Therapy/Procedure

27	Therapeutics 01/2021 - 06/2002
7	Drug Therapy (Chemotherapy) 12/2017 - 03/2002
4	Radiotherapy 09/2020 - 12/2007
2	Immunotherapy 01/2020 - 01/2016